Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series

2021 ◽  
Vol 41 (12) ◽  
pp. 6225-6230
Author(s):  
HIROSHI AOKI ◽  
NAOKI MATSUMOTO ◽  
HIROSHI TAKAHASHI ◽  
MASAYUKI HONDA ◽  
TOMOHIRO KANEKO ◽  
...  
2021 ◽  
Vol 116 (1) ◽  
pp. S786-S786
Author(s):  
Anusha Shirwaikar Thomas ◽  
Jennifer McQuade ◽  
Mehmet Altan ◽  
Yinghong Wang

ESMO Open ◽  
2021 ◽  
Vol 6 (5) ◽  
pp. 100262
Author(s):  
A. Andrikopoulou ◽  
A.M. Korakiti ◽  
K. Apostolidou ◽  
M.A. Dimopoulos ◽  
F. Zagouri

Author(s):  
Hamzah Abu-Sbeih ◽  
Cynthia Nguyen Tran ◽  
Phillip S. Ge ◽  
Manoop S. Bhutani ◽  
Mazen Alasadi ◽  
...  

2021 ◽  
Author(s):  
Mayor Ibarguren Ander ◽  
Espinosa Arranz Enrique ◽  
Peiteado Lopez Diana ◽  
Custodio Ana ◽  
Herranz Pinto Pedro

2020 ◽  
Author(s):  
David J. Byun ◽  
Rebecca Braunstein ◽  
Jessica Flynn ◽  
Junting Zheng ◽  
Robert A. Lefkowitz ◽  
...  

<b>OBJECTIVE</b> <p>To characterize immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) in a single-institution case series. </p> <p><b>DESIGN AND METHODS</b></p> <p>Retrospective chart review of 18 patients with new-onset ICI-DM following anti-PD-1/anti-PD-L1 therapy for advanced carcinomas.</p> <p><b>RESULTS</b></p> <p>9/18 patients had diabetic ketoacidosis (median glucose: 27.92mmol/L; median glucose before presentation: 6.35mmol/L). Median C-peptide at ICI-DM diagnosis was low, and declined during follow-up. Median anti-PD-1/anti-PD-L1 duration before ICI-DM was 3.65 months (range 0.56-12.23). Time to ICI-DM onset was a median 1.4 months/3 ICI cycles and 6 months/10 cycles in those positive and negative for GAD65 autoantibodies, respectively. Time to ICI-DM onset was a median 2.5 months/3 ICI cycles and 4.8 months/8 cycles after anti-PD-L1 or anti-PD-1 therapy, respectively. Significant pancreatic atrophy was seen radiographically.</p> <p><b>CONCLUSIONS</b></p> <p>ICI-DM presents abruptly, appears irreversible, is characterized by pancreatic atrophy, and may <a>occur both earlier following PD-L1 blockade compared to PD-1 inhibition </a>and in those who have positive GAD65 autoantibodies.</p>


2021 ◽  
Vol 50 (1) ◽  
pp. 326-326
Author(s):  
John Cuenca ◽  
Robert Wegner ◽  
Joshua Botdorf ◽  
Cezar Iliescu ◽  
Joseph Nates ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document